Mouse Bone Marrow Mononuclear Cells (MBMMC) Catalog #M1930-57

Bone Marrow Mononuclear Cells (BMMC) are located in the bone marrow and have regenerative capabilities. Primary BMMC are a heterogeneous population of single nucleus cells which include hematopoietic stem cells, hematopoietic progenitor cells, immature monocytes, and immature lymphocytes. Recent studies suggest that BMMC are suitable as a cell therapy to treat a variety of diseases such as cardiovascular disease, type 1 diabetes, and ischemic stroke. BMMC may also be used for bone tissue engineering. Primary mouse BMMC (MBMMC) can be utilized to further study BMMC as a potential cell therapy.

MBMMC from ScienCell Research Laboratories are isolated from healthy adult C57BL/6 mouse bone marrow. MBMMC are depleted of erythrocytes and bone marrow macrophages, cryopreserved immediately after isolation, and delivered frozen. MBMMC are a mixed population of cells that include hematopoietic stem cells and progenitor cells, monocytes, and lymphocytes. Each vial contains at least 10 million cells in 1 ml volume. MBMMC are quality control tested for viability. MBMMC are negative for mycoplasma, bacteria, yeast, and fungi. MBMMC can be maintained for a short period of time in culture using the conditions provided by ScienCell Research Laboratories. MBMMC are not intended for long-term culture and should be used promptly for experiments.

Recommended Medium

It is recommended to use HematoGro Medium (HemGM, Cat. #5501) for short-term maintenance of MBMMC in vitro.

Catalog No.	M1930-57
Country of Manufacture	United States
Product Code	MBMMC
Size/Quantity	-
Product Use	This product is for research use only. It is not approved for use in humans, animals, or in vitro diagnostic procedures.
Storage	-
Shipping Info	-
References	[1] Henrich D, Verboket R, Schaible A, Kontradowitz K, Oppermann E, Brune J, Nau C, Meier S, Bonig H, Marzi I, Seebach C. (2015) "Characterization of bone marrow mononuclear cells on biomaterials for bone tissue engineering in vitro." Biomed Res Int. 10: 1-12. [2] Savitz S, Misra V, Kasam M, Juneja H., Cox C, Alderman S, et al. (2011). "Intravenous autologous bone marrow mononuclear cells for ischemic stroke." Ann Neurol. 70:59-69. [3]Fotino C, Ricordi C, Lauriola V, Alejandro R, Pileggi A. (2010) "Bone marrow-derived stem cell transplantation for the treatment of insulin-dependent diabetes." Rev Diabet Stud. 7(2): 144-157. [4] Arnous S, Mozid A, Martin J, Mathur A. (2012) "Bone marrow mononuclear cells and acute myocardial infarction." Stem Cell Res. 3(1): 2-10.